ArticleAnti-cancer drugs2025

Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years.

Wenzhong Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.